Table 4.
Gene | Mechanism of Action and Function | References |
---|---|---|
KIT | Considered a stem cell factor and participates in vital functions of the human body, including fertility, homeostasis, and melanogenesis; its activation was detected through overexpression or mutations, and numerous Kit mutation sites are found and vary in different cancer types. | 32,33,47 |
FOXM1 | As a classic proliferation-associated transcription factor, FOXM1 directly or indirectly activates the expression of target genes at the transcriptional level and exhibits a spatiotemporal pattern whose dysregulation is involved in almost all hallmarks of tumor cells. Increased expression of FOXM1 is observed in a variety of human cancers. |
48,49 |
FGF2 | Dysregulated expression of FGF2 is associated with aggressive cancer phenotypes, enhanced chemotherapy resistance, and poor clinical outcomes. | 50,51 |
HIST1H4D | The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher-order structures. | 52 |
ZFPM2 | The effects of ZFPM2 on cell differentiation and apoptosis are suggestive of a tumor suppressor role in cancers. It is dysregulated in sex cord-derived ovarian tumors and neuroblastoma. | 53 |
IFIT2 | Has been reported to inhibit the proliferation and migration of cancer cells, regulate viral replication, and exert anticancer and IFN-mediated antiviral effects. | 54,55 |
CCNO | Has been referred to as a cyclin-like protein containing two cyclin box regulatory elements predicted to function as protein-binding domains. There have been few studies concerning the role of CCNO in cancer. | 56 |
MGP | MGP expression may be related to cellular differentiation and tumor progression. | 57,58 |
RHOBTB3 | Acts as a novel scaffolding protein for a multi-subunit complex that promotes HIFα degradation under both normoxic and hypoxic conditions, thereby suppressing the Warburg effect and preventing tumorigenesis. | 59 |
CDC7 | Overexpressed in many cancer cell lines and in certain primary tumors. | 60,61 |